Welcome To CReATe

The goal of the Clinical Research in ALS and Related Disorders for Therapeutic Development (CReATe) Consortium is to advance therapeutic development for sporadic and familial forms of amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), primary lateral sclerosis (PLS), multisystem proteinopathy (MSP), hereditary spastic paraplegia (HSP), and progressive muscular atrophy (PMA). The CReATe consortium aims to support this goal through study of the relationship between clinical phenotype and underlying genotype, and also through the discovery and development of biomarkers.

The consortium includes sites at the University of Miami, Florida; the University of Kansas Medical Center; the University of California at San Diego; California Pacific Medical Center; the University of Tübingen, Germany; the University of Pennsylvania; the University of Texas Southwestern; the University of Texas Health Sciences Center San Antonio; the University of Iowa; the University of Virginia; Wake Forest University; and Cleveland Clinic, Ohio; University of Alberta, Canada; Twin Cities ALS Consortium, Minnesota; and University of Cape Town, South Africa. The consortium is under the direction of Michael Benatar, MD, PhD, of the University of Miami.

Goals
  1. Team Science: Promote and facilitate collaborative research in the field of ALS and related disorders
  2. Trials Preparation: Establish a firm foundation for future clinical trials in homogeneous patient populations by defining phenotype-genotype relationships in ALS and related disorders
  3. Biomarkers: Identify and develop biomarkers (both wet and dry) of disease progression that may enhance therapeutic development efforts
  4. Education: Train clinician-scientists focused on therapy development for patients with ALS and related disorders
  5. Relevance to Other Rare Diseases: Pioneer an innovative approach to the study of phenotype-genotype relationships that is relevant and applicable to other rare diseases
  6. Outreach/Advocacy: Engage both the lay- and scientific-community stakeholders in a partnership that will enhance scientific research and therapeutic development for patients with ALS and related disorders
  7. Biorepository: Develop and maintain a repository of biological samples from phenotypically well-characterized individuals, for use by Consortium members and the broader scientific community, for future biomarker development